Iterum Therapeutics plc (ITRMF) Non Operating Interest Expenses (2024 - 2025)

Iterum Therapeutics has reported Non Operating Interest Expenses for 2 years, with the latest figure at $562000.0 in Q3 2025.

• On a quarterly basis, Non Operating Interest Expenses fell 25.66% year-over-year to $562000.0 in Q3 2025; TTM through Sep 2025 was $2.8 million, a N/A change from a year earlier, with the FY2024 full-year figure at $3.3 million, up 5.11% from the prior year.
• Non Operating Interest Expenses was $562000.0 for Q3 2025 at Iterum Therapeutics, up from $449000.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $1.1 million in Q4 2024, with the low at $449000.0 in Q2 2025.